Movatterモバイル変換

[0]ホーム
URL:

Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
Thehttps:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

NIH NLM Logo
Log inShow account info
Access keysNCBI HomepageMyNCBI HomepageMain ContentMain Navigation
pubmed logo
Advanced Clipboard
User Guide

Full text links

MDPI full text link MDPI Free PMC article
Full text links

Actions

Share

Review
.2022 Mar 28;13(4):599.
doi: 10.3390/genes13040599.

Pharmacogenomics: A Step forward Precision Medicine in Childhood Asthma

Affiliations
Review

Pharmacogenomics: A Step forward Precision Medicine in Childhood Asthma

Giuliana Ferrante et al. Genes (Basel)..

Abstract

Personalized medicine, an approach to care in which individual characteristics are used for targeting interventions and maximizing health outcomes, is rapidly becoming a reality for many diseases. Childhood asthma is a heterogeneous disease and many children have uncontrolled symptoms. Therefore, an individualized approach is needed for improving asthma outcomes in children. The rapidly evolving fields of genomics and pharmacogenomics may provide a way to achieve asthma control and reduce future risks in children with asthma. In particular, pharmacogenomics can provide tools for identifying novel molecular mechanisms and biomarkers to guide treatment. Emergent high-throughput technologies, along with patient pheno-endotypization, will increase our knowledge of several molecular mechanisms involved in asthma pathophysiology and contribute to selecting and stratifying appropriate treatment for each patient.

Keywords: asthma; children; corticosteroids; genetics; leukotriene antagonists; pharmacogenomics; treatment; β2-agonists.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Challenges and evidence gaps associated with pharmacogenomics in childhood asthma research and practice.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Ferrante G., La Grutta S. The Burden of Pediatric Asthma. Front. Pediatr. 2018;6:186. doi: 10.3389/fped.2018.00186. - DOI - PMC - PubMed
    1. Chung K.F. Asthma phenotyping: A necessity for improved therapeutic precision and new targeted therapies. J. Intern. Med. 2015;279:192–204. doi: 10.1111/joim.12382. - DOI - PubMed
    1. Sottile G., Ferrante G., Torregrossa M., Cibella F., Cilluffo G., Fasola S., Alessandro R., Seidita G., Viegi G., La Grutta S. An association analysis to identify genetic variants linked to asthma and rhino-conjunctivitis in a cohort of Sicilian children. Ital. J. Pediatr. 2019;45:16. doi: 10.1186/s13052-019-0603-4. - DOI - PMC - PubMed
    1. Global Initiative for Asthma (GINA) Global Strategy for Asthma Management and Prevention. 2018. [(accessed on 23 January 2022)]. Available online:https://ginasthma.org/
    1. Licari A., Brambilla I., Marseglia A., De Filippo M., Paganelli V., Marseglia G.L. Difficult vs. Severe Asthma: Definition and Limits of Asthma Control in the Pediatric Population. Front. Pediatr. 2018;6:170. doi: 10.3389/fped.2018.00170. - DOI - PMC - PubMed

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full text links
MDPI full text link MDPI Free PMC article
Cite
Send To

NCBI Literature Resources

MeSHPMCBookshelfDisclaimer

The PubMed wordmark and PubMed logo are registered trademarks of the U.S. Department of Health and Human Services (HHS). Unauthorized use of these marks is strictly prohibited.

[8]ページ先頭
©2009-2025 Movatter.jp